JP2016539935A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539935A5
JP2016539935A5 JP2016529439A JP2016529439A JP2016539935A5 JP 2016539935 A5 JP2016539935 A5 JP 2016539935A5 JP 2016529439 A JP2016529439 A JP 2016529439A JP 2016529439 A JP2016529439 A JP 2016529439A JP 2016539935 A5 JP2016539935 A5 JP 2016539935A5
Authority
JP
Japan
Prior art keywords
agent
agent according
animal
anaplerotic
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016529439A
Other languages
English (en)
Japanese (ja)
Other versions
JP6588903B2 (ja
JP2016539935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065670 external-priority patent/WO2015073803A1/en
Publication of JP2016539935A publication Critical patent/JP2016539935A/ja
Publication of JP2016539935A5 publication Critical patent/JP2016539935A5/ja
Application granted granted Critical
Publication of JP6588903B2 publication Critical patent/JP6588903B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016529439A 2013-11-14 2014-11-14 神経変性障害、ならびにその治療及び診断法 Expired - Fee Related JP6588903B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904365P 2013-11-14 2013-11-14
US61/904,365 2013-11-14
PCT/US2014/065670 WO2015073803A1 (en) 2013-11-14 2014-11-14 Neurodegenerative disorders and methods of treatment and diagnosis thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019167372A Division JP2020063233A (ja) 2013-11-14 2019-09-13 神経変性障害、ならびにその治療及び診断法

Publications (3)

Publication Number Publication Date
JP2016539935A JP2016539935A (ja) 2016-12-22
JP2016539935A5 true JP2016539935A5 (enExample) 2017-12-21
JP6588903B2 JP6588903B2 (ja) 2019-10-09

Family

ID=53058060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016529439A Expired - Fee Related JP6588903B2 (ja) 2013-11-14 2014-11-14 神経変性障害、ならびにその治療及び診断法
JP2019167372A Pending JP2020063233A (ja) 2013-11-14 2019-09-13 神経変性障害、ならびにその治療及び診断法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019167372A Pending JP2020063233A (ja) 2013-11-14 2019-09-13 神経変性障害、ならびにその治療及び診断法

Country Status (7)

Country Link
US (3) US9833430B2 (enExample)
EP (2) EP3689343A1 (enExample)
JP (2) JP6588903B2 (enExample)
AU (1) AU2014348457B2 (enExample)
CA (1) CA2929601A1 (enExample)
ES (1) ES2774321T3 (enExample)
WO (1) WO2015073803A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
AU2013358951C1 (en) 2012-12-13 2019-06-27 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
AU2014348457B2 (en) 2013-11-14 2019-04-18 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11337945B2 (en) 2016-06-01 2022-05-24 Keto Innovations, Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
NZ749389A (en) * 2016-06-08 2022-12-23 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN113917034A (zh) * 2021-10-19 2022-01-11 北京豪思生物科技有限公司 用于评估阿尔茨海默症的生物标记组合及其应用和试剂盒
US20240094216A1 (en) * 2022-08-30 2024-03-21 University Of South Carolina Odd chain fatty acid therapy for the treatment of mitochondrial diseases
EP4651868A2 (en) * 2023-01-20 2025-11-26 Keto Innovations, LLC C5 ketones for inducing weight loss and improving cognitive function
CN122458977A (zh) * 2024-03-06 2026-07-24 中国科学院昆明动物研究所 一种庚酸酯化合物及其用于制备预防和/或治疗神经退行性疾病的药物或功能食品中的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025649A (en) 1974-08-19 1977-05-24 Labaz Acetic acid derivatives having pharmacological activity and compositions containing the same
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
GB2104079B (en) 1981-08-14 1985-08-21 London Polytech New aminoacid isomers, their production and their medicinal use
US4753963A (en) 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JP3486778B2 (ja) 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
CA2361070C (en) 1999-02-05 2012-04-17 Baylor Research Institute Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US6740679B1 (en) 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
CA2389623A1 (en) 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
ES2752800T3 (es) 2000-05-01 2020-04-06 Cerecin Inc Uso de triglicéridos de cadena media para el tratamiento y la prevención de la enfermedad del Parkinson resultante de un metabolismo neuronal reducido
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
CN1756554A (zh) 2003-03-06 2006-04-05 艾克塞拉公司 新的化学实体和它们用于治疗代谢障碍的方法
EP1628622A4 (en) 2003-05-20 2008-12-17 Baylor Res Inst FIVE AND FIFTH CARBON FATTY ACIDS FOR THE TREATMENT OF METABOLISM DISORDERS AND AS FOOD SUPPLEMENTS
CA2573054C (en) 2004-07-02 2012-10-09 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
WO2006037069A1 (en) 2004-09-28 2006-04-06 Allergan, Inc. Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions
JP2011502950A (ja) 2006-09-26 2011-01-27 ベイラー リサーチ インスティテュート 栄養センサー
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
EP2179284B1 (en) 2007-07-31 2016-09-28 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
WO2009124250A1 (en) * 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for detecting tricarboxylic acid (tca) metabolic flux
KR20120129898A (ko) 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
MX2012014520A (es) 2010-06-14 2013-03-05 Baylor Res Inst Dieta de triheptanoina para tratamiento de enfermedad del cuerpo de poliglucosano (apbd).
CN113142581B (zh) * 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
EP2599482A1 (en) 2011-11-30 2013-06-05 Lunamed AG Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate)
AU2013358951C1 (en) 2012-12-13 2019-06-27 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
AU2014348457B2 (en) 2013-11-14 2019-04-18 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof

Similar Documents

Publication Publication Date Title
JP2016503793A5 (enExample)
JP2011527299A5 (enExample)
JP2014517008A5 (enExample)
JP2015143248A5 (enExample)
EP2660241A3 (en) C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21
JP2009530398A5 (enExample)
JP2012097105A5 (enExample)
EP2552203A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
JP2016511753A5 (enExample)
EP2682387A3 (en) C7-fluoro substituted tetracycline compounds
JP2013515822A5 (enExample)
HRP20210999T1 (hr) Derivati tirozina i pripravci koji ih sadrže
JP2011046708A5 (enExample)
JP2017505785A5 (enExample)
JP2012520888A5 (enExample)
JP2018537513A5 (enExample)
JP2017505809A5 (enExample)
JP2016501249A5 (enExample)
JP2016501248A5 (enExample)
WO2010094734A3 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2321265A4 (en) INOSIT- AND TREHALOSEDERIVATES AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES CONTAINING THEM
JP2011527678A5 (enExample)
EP2296665A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PREMATURE EJACULATION
EA201270653A1 (ru) Антагонист dpи его применение